CCND1 and familial pancreatic carcinoma: Cyclin D1 is known to function as an oncogene in pancreatic cancer, usually being overexpressed in these tumors [194], hence anticancer agents that are able to reduce cyclin D1 levels are beneficial for the treatment of pancreatic cancer.